How should adenosine be dosed, monitored, and what are its contraindications for acute termination of narrow-complex supraventricular tachycardia?

Adenosine for Acute Termination of Narrow-Complex Supraventricular Tachycardia

Adenosine is the recommended first-line pharmacologic agent for acute termination of narrow-complex SVT after vagal maneuvers fail, with an initial dose of 6 mg IV push followed by 12 mg if needed, achieving 90-95% conversion rates. 1

Dosing Protocol

Standard Dosing Algorithm:

• Initial dose: 6 mg rapid IV bolus (push over 1-2 seconds)
• If no conversion after 1-2 minutes: 12 mg rapid IV bolus
• If still no conversion: repeat 12 mg dose 2, 3

Important Dosing Considerations:

• Central line administration requires lower doses: Start with 3 mg centrally (77% conversion rate), as central administration is significantly more effective than peripheral 4
• Emerging evidence suggests higher initial dosing may be superior: Recent studies show 12 mg initial dose achieves 79-83% first-dose conversion versus 52-56% with 6 mg, with no increase in adverse effects 5, 6
• Weight-based dosing may optimize outcomes: Doses ≥0.1 mg/kg show improved first-dose conversion, particularly relevant given rising obesity rates 7, 8

Administration Technique:

• Give as rapid IV push (1-2 seconds) followed immediately by 20 mL saline flush
• Use large-bore peripheral IV in upper extremity, as close to central circulation as possible
• Administer with patient in supine position

Monitoring Requirements

Continuous monitoring during and immediately after administration:

• Continuous ECG monitoring is mandatory
• Electrical cardioversion equipment must be immediately available at bedside 1
• Monitor for 30-60 seconds post-injection for conversion (average time to termination: 30 seconds) 3
• Watch for premature atrial/ventricular complexes immediately after conversion, which may reinitiate tachycardia 1
• Recurrence is common: 57% of successful conversions may recur within 5 minutes and require alternative antiarrhythmic therapy 9

Critical Safety Monitoring:

• Observe for transient high-grade AV block
• Monitor blood pressure for hypotension
• Assess respiratory status (dyspnea, bronchoconstriction)
• Side effects occur in 30-36% but last <1 minute 1, 3

Absolute Contraindications

Per FDA labeling and guidelines 2:

1. Second- or third-degree AV block (unless functioning pacemaker present)
2. Sinus node disease (sick sinus syndrome, symptomatic bradycardia) without pacemaker
3. Bronchoconstrictive/bronchospastic lung disease (asthma, COPD with bronchospasm)
4. Known hypersensitivity to adenosine

Critical Warnings and Pitfalls

Life-Threatening Complications:

• May precipitate atrial fibrillation with rapid ventricular conduction leading to ventricular fibrillation 1
• Fatal cardiac events including cardiac arrest, ventricular arrhythmias, and MI have occurred 2
• Cerebrovascular accidents (hemorrhagic and ischemic) reported 2
• New-onset or recurrent seizures can occur 2

Pre-Excitation (WPW) Warning:

• NEVER use adenosine in pre-excited atrial fibrillation (wide, irregular QRS)
• In orthodromic AVRT with pre-excitation on baseline ECG, use with extreme caution as it may precipitate life-threatening AF with rapid conduction 1

Drug Interactions 2:

• Methylxanthines (caffeine, theophylline, aminophylline) antagonize adenosine - may require higher doses or be ineffective
• Dipyridamole potentiates adenosine - reduce dose or avoid
• Carbamazepine may potentiate heart block
• Withhold interacting drugs for 5 half-lives before adenosine if possible

Hemodynamic Instability:

• If patient is hemodynamically unstable, proceed directly to synchronized cardioversion rather than attempting adenosine 1

Diagnostic Utility

When adenosine fails to terminate tachycardia, it provides diagnostic information by:

• Creating transient AV block to unmask atrial activity
• Distinguishing atrial flutter, atrial fibrillation, and atrial tachycardia from AVNRT/AVRT 1, 10

Alternative Agents if Adenosine Fails

If adenosine is ineffective or contraindicated in hemodynamically stable patients 1:

• IV diltiazem or verapamil (avoid in pre-excitation, VT, or heart failure)
• IV beta-blockers
• Synchronized cardioversion

The key to successful adenosine use is rapid administration technique, immediate availability of resuscitation equipment, and recognition of absolute contraindications—particularly avoiding use in pre-excited AF where it can be lethal.